Companies / Bulgaria
If you would like to subscribe to Emerging Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Emerging Europe Pharma & Healthcare Insight please click on the trial link below.
Promising Progress Made
July 2007 | BMI ViewSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Emerging Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Emerging Europe Pharma & Healthcare Insight please click on the trial link below.
Bulgaria's pharmaceutical market is expected to experience strong growth over the next five years, reaching a valuation of approximately US$1.3bn in 2011. The market prospects have been improved by the recent alignment of local legislation with EU requirements, as well as by the country's removal from the 'Special 301' Watch List of countries with questionable intellectual property (IP) regimes, although Bulgaria has yet to catch up with the rest of the EU in this